Therapeutic Effect of Human iPS-Cell–Derived Myeloid Cells Expressing IFN-β against Peritoneally Disseminated Cancer in Xenograft Models

Chihiro Koba1,2, Miwa Haruta1,2, Yusuke Matsunaga1,2, Keiko Matsumura1,2, Eriko Haga1,2, Yuko Sasaki1,2, Tokunori Ikeda1,2, Koutaro Takamatsu1,2, Yasuharu Nishimura1, Satoru Senju1,2*

1 Department of Immunogenetics, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan, 2CREST, Japan Science and Technology Agency, Kawaguchi, Japan

Abstract
We recently developed a method to generate myeloid cells with proliferation capacity from human iPS cells. iPS-ML (iPS-cell–derived myeloid/macrophage line), generated by introducing proliferation and anti-senescence factors into iPS-cell–derived myeloid cells, grew continuously in an M-CSF–dependent manner. A large number of cells exhibiting macrophage-like properties can be readily obtained by using this technology. In the current study, we evaluated the possible application of iPS-ML in anti-cancer therapy. We established a model of peritonally disseminated gastric cancer by intraperitoneally injecting NUGC-4 human gastric cancer cells into SCID mice. When iPS-ML were injected intraperitoneally into the mice with pre-established peritoneal NUGC-4 tumors, iPS-ML massively accumulated and infiltrated into the tumor tissues. iPS-ML expressing IFN-β (iPS-ML/IFN-β) significantly inhibited the intra-peritoneal growth of NUGC-4 cancer. Furthermore, iPS-ML/IFN-β also inhibited the growth of human pancreatic cancer MiaPaCa-2 in a similar model. iPS-ML are therefore a promising treatment agent for peritonally disseminated cancers, for which no standard treatment is currently available.

Citation: Koba C, Haruta M, Matsunaga Y, Matsumura K, Haga E, et al. (2013) Therapeutic Effect of Human iPS-Cell–Derived Myeloid Cells Expressing IFN-β against Peritonally Disseminated Cancer in Xenograft Models. PLoS ONE 8(6): e67567. doi:10.1371/journal.pone.0067567

Editor: Joseph Najbauer, University of Pécs Medical School, Hungary

Received September 30, 2012; Accepted May 21, 2013; Published June 24, 2013

Copyright: © 2013 Koba et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by Grants-in-Aid Nos. 23652099 and 24300334 to Y.N. and 23559158 to S.S. from the MEXT, Japan; a grant to Y.N. from Princess Takamatsu Cancer Research Fund; Research Grant to S.S. for Intractable Diseases from Ministry of Health and Welfare, Japan; and a grant to S.S. from the Japan Science and Technology Agency (JST). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: senju@kpu.kumamoto-u.ac.jp

Introduction
Macrophages play essential roles to maintain homeostasis in the body. They reside in all tissues in the body and are engaged in various functions, such as eliminating invading pathogens, remodeling tissues, and clearing dead cells. Additionally, macrophage infiltration is frequently observed in various cancers [1]. Recent studies indicate that these tumor-associated macrophages (TAM) mainly promote progression of cancer by accelerating the local invasion and metastasis of cancers [2]. In contrast, other studies demonstrate tumoricidal effect of macrophages [3,4]. Based on the anti-cancer effects of macrophages observed in pre-clinical studies, application of macrophages to cancer therapy has been tried; for example, transfer of macrophages pre-activated with IFN-γ was tested as a potential treatment agent for cancer patients [5–9]. However, no clear therapeutic benefit against cancer has been observed thus far in the macrophage therapy.

To establish macrophage therapy as a more effective anti-cancer therapy, improving the method for supplying macrophages is necessary. In the reported clinical trials, macrophages used for therapeutic purpose were generated from donor peripheral blood monocytes that were isolated by leukapheresis. However, peripheral blood monocytes isolated from cannot be readily propagated. The number of macrophages generated by such methods is therefore limited (at most 104 to 106), and may be insufficient to achieve clinical effects. If sufficient numbers (for example, more than 1015) of macrophages with the potent anti-cancer property could be repeatedly administered, we could realize effective anti-cancer therapy with macrophages.

Pluripotent stem cells, such as embryonic stem (ES) cells or induced pluripotent stem (iPS) cells, can propagate indefinitely and possess the ability to differentiate into various types of somatic cells, including blood cells. Destruction of a human embryo is necessary to generate human ES cells. iPS cells, on the other hand, can be generated by introducing several defined factors into somatic cells derived from any donor [10–13]. Thus, iPS cell technology can overcome ethical issues as well as the histoincompatibility issue between the therapeutic donor cells and the recipient, and future application of iPS cells to clinical medicine is expected [14,15].

Several groups, including ours, have thus far established methods to generate macrophages from mouse or human pluripotent stem cells [16–24]. However, human pluripotent stem cells yield lower number of macrophages than mouse pluripotent stem cells. So far established methods generate human macrophages numbers that are less than 100 times the number of the undifferentiated iPS cells used as the starting materials; in addition, generating macrophages by conventional methods takes
more than one month. Thus, conventional methods are too laborious and expensive to be applied to practical medicine.

Recently, we established a method to induce proliferation of the iPS-cell-derived myeloid cells (iPS-MC) by lentivirus-mediated transduction of genes that can promote cell proliferation or inhibit cell senescence, such as cMYC plus BM1, EZH2, or MDM2, to generate an iPS-cell-derived myeloid/macrophage cell line (iPS-ML) [25]. iPS-ML can proliferate in an M-CSF-dependent manner for at least several months while retaining the potential to differentiate into dendritic cells (iPS-ML-DC) with a potent T cell-stimulating capacity.

In the current study, we evaluated the potential of using iPS-ML as anti-cancer effector cells. We investigated whether or not genetically modified iPS-ML expressing anti-HER2 antibody or interferon (IFN) could exert therapeutic effect against peritoneally disseminated gastric and pancreatic cancers in xenograft models.

Materials and Methods

Cells and reagents

This study was approved by ethics review board of Kumamoto University Graduate School of Medical Sciences. A human gastric cancer cell line, NUGC-4, and a human pancreatic cancer cell line, MIAPaCa-2, were provided by the Japanese Collection of Research Bioresources (JCRB, Osaka, Japan). Methods for the generation, maintenance, and genetic modification of human iPS cells have been described previously [21].

Flow cytometric analysis

The following mAbs conjugated with FITC or PE were purchased from BD Pharmingen (San Diego, CA), Beckman Coulter (Brea, CA), Miltenyi Biotec (Bergish-Gladbach, Germany), Sigma (St. Louis, MO), or eBioscience (San Diego, CA): anti-CD45 (clone HI30, mouse IgG1), anti-CD33 (WM53, mouse IgG1), anti-CD36 (FA6.152, mouse IgG1), anti-CD11b (JCRF44, mouse IgG1), anti-CD14 (61D3, mouse IgG1), anti-CD4 (1830, mouse IgG2a), anti-CD97 (VIM3b, mouse IgG1), anti-CD13 (WM15, mouse IgG1), anti-CD87 (62022, mouse IgG1), anti-CD115 (2-3A5-1B10, rat IgG2a), anti-CD116 (4H1, mouse IgG1), anti-TLR2 (T2.5, mouse IgG1), anti-TLR4 (HTA125, mouse IgG2a), anti-HER2/neu (Neu 24.7, mouse IgG1), and anti-cMYC (9E10, mouse IgG1). Isotype-matched controls, mouse IgG2a, anti-HER2/neu (Neu 24.7, mouse IgG1), and anti-cMYC (9E10, mouse IgG1), were isolated by a previously described method [21]. Subsequently, iPS cells carrying the anti-HER2 scFV construct were placed into differentiation culture to generate iPS-MC/anti-HER2. The iPS-ML expressing scFv specific to HER2 were transduced with lentivirus vectors for cMYC plus BM1, or cMYC plus EZH2, to generate iPS-ML. The method for generating and maintaining iPS-ML has been previously reported [25].

Generation of iPS-ML expressing scFv

A plasmid vector (pCAG-IREs-Puro) encoding anti-HER2 scFv was introduced into human iPS cells by electroporation and selected using puromycin (5 μg/mL). Stably transfected clones were isolated by a previously described method [21]. Subsequently, iPS cells carrying the anti-HER2 scFv construct were placed into differentiation culture to generate iPS-MC/anti-HER2. The iPS-ML expressing scFv specific to HER2 were transduced with lentivirus vectors for cMYC plus BM1, or cMYC plus EZH2, to generate iPS-ML. The method for generating and maintaining iPS-ML has been previously reported [25].

Genetic modification of iPS-ML/scFv to express additional factors

iPS-ML were transduced with lentivirus vector encoding IFN-α, IFN-β, IFN-γ, TNF-α, FAS-ligand, or TRAIL. To select cells stably expressing the transgenes, the cells were cultured in a medium containing hygromycin (0.5~2 ng/mL). To quantitate the production of transgene-derived cytokines and FAS-ligand, the transfected iPS-ML were cultured (1×10⁶ cells/well in 200 μL) in 96-well flat-bottomed culture plates for 24 hours, and the concentration of cytokines and FAS-ligand in the culture supernatant was measured by using ELISA kits purchased from Endogen or R&D Systems. TRAIL expression was examined by flow cytometric analysis.

Analysis of cancer cell sensitivity to cytokines

NUGC-4 or MIAPaCa-2 cells were cultured (4×10⁵ cells/well in 1 mL) in 24-well culture plates in the presence or absence of 10 ng/mL recombinant IFN-α, IFN-β, IFN-γ, or TNF-α for 24 hours. Subsequently, the cells were recovered and stained with FITC-labeled Annexin-V (Biovision, Mountain View, CA) and analyzed on a FACScan flow cytometer. Luciferase-expressing cancer cells were cultured (5×10⁶ cells/well in 200 μL) in 96-well culture plates (B&W Isoplate, Wallac) in the presence of 10 ng/mL recombinant IFN-α, IFN-β, IFN-γ, or TNF-α. Three days later, luciferase substrate solution (SteadyLite Plus, Perkin-Elmer) was added (50 μL/well), and luminescence was measured on a micro-plate reader (TriStar, BertholdTech, Bad Wildbad, Germany).

Analysis of anti-tumor activity of iPS-ML in vitro

NUGC-4 cells (5×10⁵ cells/well) expressing luciferase were cultured with or without iPS-ML (2.5×10⁶ cells/well) in 96-well flat-bottomed culture plates (B&W Isoplate, Perkin-Elmer). After a
Results

Analysis of iPS-ML infiltration into cancer tissues in SCID mice

Mouse experiments were approved by the animal research committee of Kumamoto University. Green fluorescence protein (GFP)-expressing NUGC-4 cells (5 × 10⁶ cells/mouse) were injected into the peritoneal cavity of SCID mice. After 15 days, iPS-ML were labeled with PKH26 (Sigma), following the manufacturer’s instructions, and were intraperitoneally (i.p.) injected into the mice (3 × 10⁶ cells/mouse). Mice were sacrificed the following day and subjected to fluorescence analysis to macroscopically detect the location of NUGC-4 tumors and iPS-ML on a NightOwl II (Berthold Technologies, Bad Wildbad, Germany). NUGC-4/GFP was detected with 475 nm excitation and 520 nm emission filters. For microscopic examination, cancer tissues in the greater omentum were removed, fixed in 4% paraformaldehyde/PBS, and embedded in Tissue-Tek OCT compound (Sakura Finetechnical, Tokyo, Japan). Tissue sections of 20-μm thickness were made on a cryostat and analyzed on a fluorescence microscope (Axio Observer Z1, Carl Zeiss, Oberkothen, Germany).

Analysis of anti-tumor activity of iPS-ML in vivo

SCID mice were i.p. injected with the cancer cells (5 × 10⁶ cells/mouse). On day 3 or 4, the mice were subjected to luminescence image analysis to examine tumor establishment. Subsequently, mice with established tumors were randomly divided into treatment and control groups. Mice in the treatment group were injected with iPS-ML according to the indicated schedule, and cancer cell growth was monitored in mice by luminescence imaging analysis. The magnitude of cancer growth was determined by the change of total luminescence counts for each mouse.

Results

Characterization of human iPS-cell–derived proliferating myeloid cells

We previously established a procedure to generate myelomonocytic cells with proliferating capacity (iPS-MC) by lentivirus-mediated transduction of cMYC plus BM1-I into human iPS cells [25]. iPS-ML grew mostly in suspension in an M-CSF–dependent manner. They expressed several macrophage makers, and were heterogeneous in the morphology and in the expression of some of the cell surface molecules (Fig. 1A, B).

To analyze the phagocytic ability of iPS-ML, we microscopically observed the iPS-ML culture after adding FITC-labeled zymosan particles. After a 90-min incubation, fluorescence signals were detected in most cells, indicating that most of the iPS-ML ingested zymosan particles (Fig. 1C). Approximately 60% of the iPS-ML contained zymosan particles after 40 min incubation with FITC-labeled zymosan particles, as assessed by flow cytometric analysis (Fig. 1D). A time course for phagocytosis is shown in Figure 1E.

Anti-cancer activity of iPS-ML expressing anti-Her2 scFv in vitro

A cancer-related antigen, HER2/neu, is expressed by various kinds of human cancers, including breast and gastric cancers [28]. We decided to examine the anti-cancer effect of iPS-ML expressing anti-Her2 scFv against a HER2-expressing gastric cancer cell line, NUGC-4 (Fig. 2A). For this purpose, we generated iPS-ML stably expressing anti-Her2 scFv (iPS-ML/anti-HER2) (Fig. 2B). iPS-ML/anti-HER2 were generated from iPS-MC derived from an iPS cell clone introduced with an expression vector for anti-Her2 scFv by a previously described method [21]. We sporadically examined and confirmed the expression of the scFv by iPS-ML/anti-HER2.

At first we evaluated the effect of iPS-ML/anti-HER2 against NUGC-4 cells in vitro. Firefly luciferase-introduced NUGC-4 cells were co-cultured with iPS-ML with or without anti-Her2 scFv expression. We observed that iPS-ML reduced live NUGC-4 cells, and that expression of anti-HER2 scFv in iPS-ML enhanced the inhibitory effect against the growth of NUGC-4 cells (Fig. 2C).

Accumulation and infiltration of i.p. injected iPS-ML in tumor tissues

We wanted to evaluate whether iPS-ML had a therapeutic effect on peritoneally disseminated cancer. Macrophage infiltration is frequently observed in clinical samples of cancer tissue [1]. We examined whether or not i.p. administered iPS-ML infiltrated into cancer tissues pre-established in the peritoneal cavity of mice.

To this end, GFP-expressing NUGC-4 human gastric cancer cells, established from a peritoneal metastatic lesion of a diffuse-type gastric cancer patient, were injected i.p. into SCID mice. After 15 days, iPS-ML labeled with red fluorescent dye PKH26 were injected. We simultaneously injected recombinant tissue plasminogen activator (tPA) into the mouse peritoneal cavity, expecting that tPA promoted the infiltration of iPS-ML into tumor tissues. Mice were sacrificed on the following day, and dissected to determine the location of the injected iPS-ML by fluorescence analysis.

Macroscopic fluorescence analysis detecting GFP (excitation/emission: 475/520 nm) indicated that NUGC-4 tumors mainly localized in the greater omentum (Fig. 3A). Injected iPS-ML detected by PKH26 fluorescence (excitation/emission: 550/600 nm) were also mostly localized in the greater omentum, demonstrating that iPS-ML efficiently accumulated into the tumor tissues. Such a clear accumulation of iPS-ML into the greater omentum was not observed when iPS-ML were inoculated into the mice without established tumors (data not shown).

We then isolated and microscopically examined the tumor tissues. In the tissue section shown in Figure 3B, PKH26-labeled iPS-ML infiltrated into the nest of GFP-expressing NUGC-4 cells. Similar experiments were done without tPA injection, and higher magnification analysis of the tissue sections clearly shows the infiltration of iPS-ML into cancer tissue (Fig. 3C, D). These results indicate that iPS-ML efficiently infiltrated into the cancer tissues, when i.p. injected into mice carrying cancers established in the peritoneal cavity.

No anti-cancer activity of iPS-ML expressing anti-Her2 scFv in vivo

We next examined the effect of iPS-ML/anti-HER2 against NUGC-4 in vivo. Luciferase-expressing NUGC-4 cells were inoculated into the peritoneal cavity of SCID mice (5 × 10⁶ cells/mouse). After 3 days, cancer cell engraftment in the mice was examined by bioluminescence analysis, and mice bearing cancer cells were randomly divided into treatment or control groups. From days 4 to 8, the treatment group mice were injected daily with iPS-ML/anti-HER2 (2 × 10⁷ cells/mouse). On day 10, the mice were subjected to bioluminescence analysis again to examine the progression of the cancer.
As shown in Figure S1, NUGC-4 tumors in the iPS-ML-treated mice grew even faster than in the control mice. They rather enhanced NUGC-4 cancer cell growth in this \textit{in vivo} model, although statistically non-significant. This may be because iPS-ML/anti-HER2 were affected by the cancer microenvironment to acquire a pro-cancer phenotype.

Figure 1. Characterization of iPS-ML as macrophages. \textbf{A.} A phase-contrast image of live iPS-ML in a culture plate (upper) and an image of iPS-ML stained with May-Giemsa on a slide glass (lower) are shown. \textbf{B.} Cell-surface expression of macrophage marker molecules CD11b, CD14, CD4, CD13, CD33, CD36, CD87, CD97, CD115, CD116, TLR2, and TLR4 on iPS-ML was analyzed by flow cytometry. The staining profiles of the specific mAb (thick lines) and an isotype-matched control mAb (grey area) are shown. \textbf{C.} iPS-ML in culture plates were added with FITC-labeled zymosan particles. Phase-contrast (upper) and fluorescence (lower) images after a 90-min incubation are shown. \textbf{D.} After a 40-min incubation in the presence or absence of zymosans, cells were harvested using trypsin/EDTA and then analyzed on a flow cytometer. Percentages of cells with high fluorescence intensity indicating intracellular zymosan are shown. \textbf{E.} Time course for phagocytosis is shown. Data shown are mean ± SD of duplicate assays.

doi:10.1371/journal.pone.0067567.g001

As shown in Figure S1, NUGC-4 tumors in the iPS-ML-treated mice grew even faster than in the control mice. They rather enhanced NUGC-4 cancer cell growth in this \textit{in vivo} model, although statistically non-significant. This may be because iPS-ML/anti-HER2 were affected by the cancer microenvironment to acquire a pro-cancer phenotype.

Figure 2. Effect of iPS-ML/anti-HER2 against HER2-expressing NUGC-4 gastric cancer cells \textit{in vitro}. \textbf{A.} HER2/neu expression on NUGC-4 human gastric cancer cells was analyzed. The staining profiles of anti-HER2 mAb (thick line) and an isotype-matched control antibody (grey area) are shown. \textbf{B.} Cell-surface expression of anti-HER2 scFv on iPS-ML (iPS-ML/anti-HER2) was detected by staining with an anti-cMYC-tag antibody. \textbf{C.} Luciferase-expressing NUGC-4 cells (5 x 10^3 cells/well) were cultured alone or co-cultured in a 96-well culture plate with iPS-ML (1 x 10^4 cells/well) with or without anti-HER2 scFv expression. The number of live NUGC-4 cells was measured by luciferase activity after 3-day culture. The data are indicated as the mean ± SD of duplicate assays.

doi:10.1371/journal.pone.0067567.g002
Sensitivity of NUGC-4 cells to cytokines and cell-killing molecules

To make iPS-ML able to overcome the cancer microenvironment and to exert anti-cancer effects in vivo, we determined to further modify iPS-ML/anti-HER2 to express additional molecules. Cytokines, such as IFNs, are known to induce death or inhibit growth of cancer cells [29,30]. In addition, these cytokines are known to enhance the anti-cancer activity of macrophages [31–33].

We analyzed the sensitivity of NUGC-4 cells to recombinant IFN-α, IFN-β, IFN-γ, or TNF-α. After a 24-hour incubation in the presence either of these factors (10 ng/mL), we analyzed apoptosis by staining the cells with FITC-labeled annexin-V. We observed that all tested cytokines induced certain levels of NUGC-4 cell apoptosis (Fig. S2A). To examine the effect to reduce the number of live NUGC-4 cells, luciferase-expressing NUGC-4 cells were cultured for 3 days in the presence of these factors. Consistent with the annexin-V-staining data, all tested cytokines significantly decreased the number of live NUGC-4 cells (Fig. S2B). In both assays, IFN-β and IFN-γ exhibited the most profound effect.

Generation of iPS-ML/anti-HER2 expressing additional molecules

We generated lentivirus expression vectors for the IFNs and TNF-α, and introduced them into iPS-ML/anti-HER2. In addition, we introduced lentivirus expression vectors for “apoptosis-inducing factors”, FAS-ligand or TRAIL. We were able to generate transfected iPS-ML that produced cytokines at more than 3 ng/24 hour/10⁶ cells, except for IFN-γ (Fig. S3A). We could generate transfectant iPS-ML producing only a low level of IFN-γ, probably because of toxicity of IFN-γ to iPS-ML. Cell surface expression of TRAIL in the transfected iPS-ML was confirmed by flow cytometric analysis (Fig. S3B).

We co-cultured the iPS-ML/anti-HER2 expressing additional anti-cancer molecules with luciferase-expressing NUGC-4 cells and analyzed the number of live NUGC-4 cells based on luciferase activity after 3 days (Fig. 4). iPS-ML/anti-HER2 expressing IFN-α, IFN-β, or TRAIL showed a more profound effect to reduce NUGC-4 cells than iPS-ML/anti-HER2, and those expressing IFN-β were the most potent. iPS-ML/anti-HER2 expressing IFN-γ or TNF-α exhibited an effect similar to iPS-ML/anti-HER2. The lack of significant enhancement of the anti-NUGC-4 effect by IFN-γ transduction may be due to that the amount of IFN-γ produced by iPS-ML/anti-HER2/IFN-γ was lower than the level to exert anti-cancer effect. In this experiment, forced expression of FAS-ligand unexpectedly weakened the anti-NUGC-4 effect of iPS-ML/anti-HER2.

Therapeutic effect of iPS-ML/IFN-β on peritoneally disseminated NUGC-4 gastric cancer cells in SCID mice

Based on the results of in vitro experiments, we examined the in vivo anti-NUGC-4 effect of iPS-ML/anti-HER2 expressing either IFN-α, IFN-β, or TRAIL. Treatment with neither iPS-ML/anti-HER2/IFN-α nor iPS-ML/anti-HER2/TRAIL showed clear inhibitory effect on the cancer cell growth in vivo (data not shown). On the other hand, iPS-ML expressing IFN-β exhibited significant effect to inhibit the growth of the cancer as described below.

In the experiments shown in Figure 5, growth of NUGC-4 tumors was monitored by bioluminescence analysis on days 4, 10 and 17 after the cancer cell inoculation. Mice bearing NUGC-4 tumors on day 4 were divided into therapy or no-therapy (control)
group. Mice of the therapy groups were injected i.p. with iPS-ML/IFN-$\beta$ or iPS
ML/anti-HER2/IFN-$\beta$ from day 4 (2 $\times 10^7$ cells/injection/mouse, 3 injections per
week). Figure 5A shows the
image data of the luminescence analysis of the mice. Figure 5B
indicates the fold change of luminescence activity from day 4 of
the control and treatment groups, demonstrating that tumor
growth was inhibited by treatment with iPS-ML/IFN-$\beta$
or iPS-ML/anti-HER2/IFN-$\beta$. iPS-ML/IFN-$\beta$
and iPS-ML/anti-HER2 were equivalently effective, indicating that expres-
sion of anti-HER2 is dispensable for anti-cancer effect of iPS-ML
producing IFN-$\beta$.

Figure S4 shows the results of similar experiments to
comparatively examine the effects of iPS-ML, iPS-ML/IFN-$\beta$
iPS-ML/anti-HER2, and recombinant IFN-$\beta$ against NUGC-4
cancer in vivo. In consistent with the data shown in Figure 5,
treatment with iPS-ML/IFN-$\beta$ significantly suppressed the pro-
gression of cancer. On the other hand, both iPS-ML and iPS-ML/
anti-HER2 rather promoted the growth of cancer, although
statistically nonsignificant. Injection of 400 ng but not 200 ng/
mouse/injection of recombinant IFN-$\beta$ on the same schedule as
iPS-ML injection exhibited some inhibitory effect on the tumor
growth, although the effect was not statistically significant.

Collectively, simple iPS-ML did not exhibit anti-cancer effect in vivo. Genetic
modification to produce IFN-$\beta$ conferred significant
anti-cancer activity to iPS-ML. On the other hand, expression of
anti-HER2 scFv did not have such effect.

Therapeutic effect of iPS-ML/IFN-$\beta$ against pancreatic
cancer in a xenograft model

We next examined the effect of iPS-ML/IFN-$\beta$ treatment
against pancreatic cancer cells. Addition of recombinant IFN-$\beta$
to
MIAPaCa-2 human pancreatic cancer cells induced apoptosis and
reduced the number of live cells in in vitro experiments (Fig. S5).

We examined the effect of iPS-ML/IFN-$\beta$ against MIAPaCa-2
cells in vivo. We could establish a peritoneal cancer model by i.p.
injection of the MIAPaCa-2 cells expressing luciferase into SCID
mice. In the experiments shown in Figure 6, 6 mice were treated
with iPS-ML/IFN-$\beta$ injection 3 times per week for 2 weeks from
day 4; the results of the 8 control mice without treatment are also
shown. We observed that iPS-ML/IFN-$\beta$ treatment significantly
inhibited MIAPaCa-2 tumor growth as compared with control
mice. The decrease in the average luminescence count from day
10 to day 17 of the control (no therapy) group should have been
due to the increase of ascites caused by the cancer, because we
observed progressive enlargement of the abdomen in the mice of
this group. The results shown in Figure 6 suggest that the therapy
with iPS-ML/IFN-$\beta$ is effective against pancreatic cancer.

Discussion

Macrophage infiltration is frequently observed in clinical
samples of solid cancers, and these macrophages are called
TAM. In the present study, we observed that i.p. injected iPS-ML
efficiently accumulated and infiltrated into pre-established cancer
tissues in the peritoneal cavity of SCID mice (Fig. 3). To examine
the tissue infiltration of intravenously administered iPS-ML, we
injected PKH26-labeled iPS-ML via tail vein into the mice
carrying cancer in the peritoneal cavity. However, we could not
detect evident accumulation of iPS-ML in the cancer tissue in this
experiment. In the mice, i.e. injected iPS-ML should have
distributed systemically, and we could inject at most 2 $\times 10^6$
of
iPS-ML into the tail vein. Thus, i.e. injectable iPS-ML were not
sufficient to be detected in the intra-peritoneal cancer tissues by
macroscopic or histological analysis.
Intending to confer anti-cancer activity to iPS-ML, we generated iPS-ML expressing scFv specific for human HER2/neu. The scFv was linked to the trans-membrane and cytoplasmic domains of FcγRI. Expression of anti-HER2 scFv made the iPS-ML able to reduce the growth of HER2-expressing gastric cancer cells, NUGC-4, in vitro (Fig. 2). However, iPS-ML/anti-HER2 promoted rather than inhibited the progression of cancer in vivo (Fig. 4).

Local cytokine milieu is the critical factor determining whether TAM exert pro- or anti-tumor activity [1]. It is considered that TAM are affected by the cancer microenvironment and polarized to M2 phenotype in most cases. In similar to the naturally

Figure 5. Effect of iPS-ML producing IFN-β with or without anti-HER2 treatment to inhibit the growth of peritoneally disseminated NUGC-4 cells. Luciferase–expressing NUGC-4 cells were injected i.p. into SCID mice (5 × 10^6 cells/mouse). On day 4, the mice were subjected to the luminescence imaging analysis. Mice were injected on days 4, 6, 8, 11, 13, and 15 with iPS-ML/IFN-β or iPS-ML/IFN-β/anti-HER2 (2 × 10^7 cells/mouse for each injection, n = 5 for each group). As a control, 8 mice were left untreated. All mice were subjected to bioluminescence analysis on days 10 and 17. A. The luminescence images are shown. B. For each mouse, the luminescence signal was calculated as a relative value, where the photon count on day 4 was defined as 1. The mean ± SD of fold-change from day 4 in control and treatment groups are shown.

doi:10.1371/journal.pone.0067567.g005

Figure 6. Inhibition of MIAPaCa-2 pancreatic cancer cell growth by iPS-ML/IFN-β. Luciferase–expressing MIAPaCa-2 cells were inoculated i.p. into SCID mice (5 × 10^6 cells/mouse), and the mice were subjected to luminescence imaging analysis on day 3. Mice engrafted with cancer cells were randomly divided into treatment (n = 6) and control (n = 8) groups. Mice in the treatment group were injected with iPS-ML/IFN-β (2 × 10^7 cells/mouse for each injection) on days 4, 6, 8, 11, 13, and 15. All mice were subjected to bioluminescence analysis on days 10 and 17. The luminescence images are shown in A. For each mouse, the change of luminescence signal per mouse was calculated as a relative value, where the photon count on day 3 was defined as 1. The mean ± SD of the fold change in control and treatment groups are shown in B.

doi:10.1371/journal.pone.0067567.g006
Most of allo-reactive CD8+ T cells (the major immune effector cells mediating acute rejection) upon cell transfer to allogeneic recipients [40–42].

Nevertheless, the allo-reactive CD8+ T cells recognizing HLA class I-bound peptides presented via the TAP-independent pathway (mainly derived from signal peptides) may eventually eliminate the transferred allogeneic iPSC-ML. Additionally, since the HLA class II molecules are intact even in TAP-deficient iPSC-ML, allo-reactive CD4+ T cells may also attack these cells. Collectively, we predict that the injected iPSC-ML will survive in the recipients for several days to exert the anti-cancer effect, but will then be completely eliminated by the recipient’s immune system. Thus, we consider that therapy with allogeneic TAP-deficient iPSC-ML is effective and safe.

In summary, iPSC-ML accumulated and infiltrated into the tumor tissues upon i.p. injection into SCID mice bearing peritoneally implanted cancer. iPSC-ML expressing IFN-β inhibited the growth of MiaPaCa-2 pancreatic cancer as well as NUGC-4 gastric cancer in xenograft models. Although we reasoned that adoptive anti-cancer cell therapy with TAP-deficient allogeneic iPSC-ML is effective and safe, further preclinical study is necessary.

Supporting Information

Figure S1 No effect of iPSC-ML/anti-HER2 on the growth of peritoneally disseminated NUGC-4 cells. Luciferase-expressing NUGC-4 cells (5 × 10^6 cells/mouse) were injected into the peritoneal cavity of SCID mice. After 3 days, mice were subjected to bioluminescence analysis to detect cancer cells in the peritoneal cavity. Mice exhibiting evident lucinescence signals were randomly divided into control (n = 6) and therapy (n = 3) groups. Mice in the therapy group were injected i.p. with iPSC-ML/anti-HER2 (2 × 10^7 cells/mouse each day) daily from days 4–8. On day 10 or 11, the mice were analyzed again to analyze tumor growth. A. The lucinescence images on day 3 and day 10/11 are shown. B. For each mouse, fold change in lucinescence signal from day 3 to day 10/11 was calculated. The mean ± SD of fold change for each group is shown. (TIF)

Figure S2 Effect of TNF-α and IFNs to induce apoptosis of NUGC-4 cells. A. NUGC-4 cells were cultured in a 24-well culture plate (2.5 × 10^4 cells/well in 1 mL) in the presence or absence of TNF-α/IFN-γ, IFN-β, or IFN-γ all 10 ng/mL. After 3 days, cells were recovered, stained with FITC-labeled Annexin-V, and analyzed on a flow cytometer to detect apoptotic cells. The numbers in the figures indicate the percentage of cells positively stained with annexin-V. B. Luciferase-expressing NUGC-4 cells (5 × 10^6 cells/well) were cultured in a 96-well culture plate in the presence or absence of TNF-α, IFN-γ, IFN-β, or IFN-γ (10 ng/mL). The number of live NUGC-4 cells was measured by luciferase activity after a 3-day culture. The data are indicated as the mean ± SD of triplicate assays. (TIF)

Figure S3 Generation of iPSC-ML expressing IFNs, TNF-α, or TRAIL along with anti-HER2 scFv. A. iPSC-ML transduced with lentivirus vector for IFNs, TNF-α, or FAS-ligand were cultured (2 × 10^6 cells/well in 200 µL) in 96-well culture plates. After 24 hours, culture supernatant was collected, and the concentration of each cytokine was measured by ELISA. Culture medium alone and iPSC-ML/anti-HER2 supernatant were also analyzed as controls. B. Cell-surface expression of TRAIL on iPSC-ML transduced with the TRAIL expression vector was examined by flow cytometric analysis. The staining profiles of the specific
mAb (thick line) and an isotype-matched control mAb (grey area) are shown. (TIF)

Figure S4 Effect of iPS-ML/IFN-β and recombinant IFN-β on peritoneally disseminated NUGC-4 cells. Luciferase-expressing NUGC-4 cells were injected i.p. into SCID mice (5 × 10^5 cells/mouse). On day 3, the mice were subjected to the luminescence imaging analysis. Mice were injected on day 4, 6, and 8 with iPS-ML (2 × 10^5 cells, n = 5), iPS-ML/anti-HER2 (2 × 10^5 cells, n = 5), iPS-ML/IFN-β (2 × 10^5 cells, n = 5), 200 ng of recombinant IFN-β (n = 5), or 400 ng of recombinant IFN-β (n = 4). As a control, 5 mice were left untreated. All mice were subjected to bioluminescence analysis again on day 11. A. The luminescence images are shown. B. For each mouse, fold change in luminescence signal from day 3 to day 11 was calculated. The mean ± SD of fold change for each group is shown. (TIF)

Figure S5 Effect of IFN-β to induce apoptosis of MIApCa2-2 cells in vitro. A. MIApCa2-2 cells were cultured in a 24-well culture plate (2.5 × 10^3 cells/well in 1 mL) in the presence or absence of IFN-β (10 ng/mL). After 3 days, cells were recovered, stained with FITC-labeled Annexin-V, and analyzed on a flow cytometer to detect apoptotic cells. The numbers in the figures indicate the percentage of cells positively stained with annexin-V. B. Luciferase-expressing NUGC-4 cells (5 × 10^5 cells/well) were cultured in a 96-well culture plate in the presence or absence of IFN-β (10 ng/mL). The number of live NUGC-4 cells was measured by luciferase activity after a 3-day culture. The data are indicated as mean ± SD of triplicate assays. (TIF)

Acknowledgments

NUGC-4 and MIApCa2-2 were provided by the Japanese Collection of Research Bioresources [JCRB, Osaka, Japan]. The plasmids for preparing recombinant lentivirus, pCMV-EGFP, and pCAG-HIVgp were kindly provided by Dr. H. Miyoshi [RIKEN BioResource Center]. cDNA clones for human IFN-α, IFN-β IFN-γ, TNF-α, TRAIL, FAS-ligand, and IFN-α were provided by NITE Biological Resource Center [Kazusa, Japan], Kazusa DNA Research Center [Kazusa, Japan], or RIKEN BRC (Tsukuba, Japan), which is participating in the National Bioresources Project of the Ministry of Education, Culture, Sports, Science, and Technology (MEXT), Japan.

Author Contributions

Conceived and designed the experiments: CK MH YM SS. Performed the experiments: CK MH YM KM SS. Analyzed the data: CK MH YN SS. Contributed reagents/materials/analysis tools: CK MH YM KM EH SS. Wrote the paper: CK MH SS.

References

1. Lewis CE, Pollard JW (2006) Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605–612.
2. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A (2006) Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25: 313–329.
3. Bonomte B, Larmonier N, Favre N, Fromentin A, Moutet M, et al. (2001) Identification of tumor-infiltrating macrophages as the killers of tumor cells after immunization in a rat model system. J Immunol 167: 5077–5083.
4. Shin H, Matsumoto M, Oshimi H, Tanaka S, Nakane A, et al. (2012) Toll-like receptor 1 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A 109: 2066–2071.
5. Andreesen R, Scheibenbogen C, Brugger W, Krause S, Meerpohl HG, et al. (1998) Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res 58: 7430–7436.
6. Andreesen R, Herrmann B, Krause SW (1998) Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 64: 419–426.
7. Klimp AH, de Vries GL, Scherphof GL, Daemen T (2002) A potential role of cytokine-producing macrophages in the activation of human melanoma cells. J Immunol 169: 143–161.
8. Klimp AH, de Vries GL, Scherphof GL, Daemen T (2002) A potential role of cytokine-producing macrophages in the activation of human melanoma cells. J Immunol 169: 143–161.
9. Baron-Bodo V, Doceur P, Lefebvre ML, Labroquere K, Defaye C, et al. (2005) Involvement of CD43 on monocytes in the expression of the adhesion molecules P-selectin and ICAM-1. J Immunol 174: 6172–6180.
10. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, et al. (2002) Intrapleural instillation of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 121: 1921–1927.
11. Barou-Bodo V, Durieux M, Lefebvre ML, Labroquere K, Defaye C, et al. (2005) Anti-tumor properties of human-activated macrophages produced in large scale for clinical application. Immunobiology 210: 267–277.
12. Takahashi K, Yamakawa S (2006) Induction of phagocytic stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–673.
13. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861–872.
14. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, et al. (2007) Induction of pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920.
15. Park HJ, Zhao R, West JA, Yabuchi A, Hsu H, et al. (2008) Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141–146.
16. Kaufman DS (2009) Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood 114: 3513–3523.
17. Lindmark H, Rosengren B, Hurt-Camejo E, Bruder CE (2004) Gene expression profiling shows that macrophages derived from mouse embryonic stem cells is an improved in vitro model for studies of vascular disease. Exp Cell Res 300: 335–340.
18. Odedra J, Vats D, Zhang L, Ricardo-Gonzalez R, Smith KL, et al. (2007) Quantitative expansion of ES cell-derived myeloid progenitors capable of differentiating into macrophages. J Leukoc Biol 81: 711–719.
19. Choi KD, Vodyanik MA, Slukvin I (2009) Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD13+CD14+ progenitors. J Clin Invest 119: 2818–2829.
20. Senju S, Haruta M, Matsunaga Y, Fukushima S, Ikeda T, et al. (2009) Characterization of dendritic cells and macrophages generated by directed differentiation from mouse induced pluripotent stem cells. Stem Cells 27: 1021–1031.
21. Senju S, Haruta M, Matsunaga K, Matsunaga Y, Fukushima S, et al. (2011) Generation of dendritic cells and macrophages from human induced pluripotent stem cells using lentivirus-based vector systems. Cell Transplant 18: 873–884.
22. Karlsson KR, Cossey S, Martinez FO, Shaw M, Minger SL, et al. (2008) Homogeneous monocytes and macrophages from human embryonic stem cells following coculture-free differentiation in M-CSF and IL-3. Exp Hematol 36: 1167–1175.
23. Grögeriadis AE, Kennedy M, Bozeć A, Brunton F, Stenbeck G, et al. (2010) Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood 115: 2769–2776.
24. Klümbenno O, Di Stefano A, Georger B, Hamdi S, Opolou P, et al. (2011) Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. Blood 117: 3065–3075.
25. Haruta M, Tomita Y, Uno A, Matsunaga K, Ikeda T, et al. (2012) TAP-deficient human iPS cell-derived myeloid cell lines as unlimited cell source for dendritic cell-like antigen-presenting cells. Gene Ther. Epub ahead of print.
26. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, et al. (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23: 709–717.
27. Miyoshi H, Blumer U, Takahashi M, Gage FH, Verma IM (1998) Development of a self-inactivating lentivirus vector. J Virol 72: 8150–8157.
28. Gravalla G, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19: 1523–1529.
29. Kamiyasu H, Yatsu W, Kirahara K, Naka K, Yokozaki H, et al. (1997) Growth inhibitory effect of interferon-beta is associated with the induction of cyclin-dependent kinase inhibitor p27Kip1 in a human gastric carcinoma cell line. Cell Growth Differ 8: 47–52.
30. Shyu RY, Yu HL, Yu JC, Jiang SY (2000) Direct growth suppressive activity of interferon-alpha and -gamma on human gastric cancer cells. J Surg Oncol 75: 122–130.
31. Pace JL, Russell SW, Torres BA, Johnson HM, Gray PW (1983) Recombinant mouse gamma interferon induces the priming step in macrophage activation for tumor cell killing. J Immunol 130: 2011–2013.
32. Celada A, Gray PW, Rinderknecht E, Schreiber RD (1984) Evidence for a gamma-interferon receptor that regulates macrophage tumoricidal activity. J Exp Med 160: 55–74.
33. Pace JL, Russell SW, LeBlanc PA, Murasko DM (1985) Comparative effects of various classes of mouse interferons on macrophage activation for tumor cell killing. J Immunol 134: 977–981.
34. Adam Z, Vorlicek J (1994) Therapeutic use of interferon beta. Vnitr Lek 40: 329–333.
35. Roukos DH (2000) Current status and future perspectives in gastric cancer management. Cancer Treat Rev 26: 243–255.
36. Kim DY, Joo JK, Park YK, Ryu SY, Kim YJ, et al. (2006) Prognostic factors in gastric carcinoma with peritoneal dissemination. Acta Chir Belg 106: 665–668.
37. Yonemura Y, Endo Y, Obata T, Sasaki T (2007) Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites. Cancer Sci 98: 11–18.
38. Li D, Abbruzzese JL (2010) New strategies in pancreatic cancer: emerging epidemiologic and therapeutic concepts. Clin Cancer Res 16: 4313–4318.
39. Neefjes JJ, Momburg F, Hammerling GJ (1993) Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science 261: 769–771.
40. Loyer V, Fontaine P, Pison S, Hetu F, Roy DC, et al. (1999) The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes. J Immunol 163: 6462–6467.
41. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F (2000) CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 164: 3095–3101.
42. Matsunaga Y, Fukuda D, Hirata S, Fukushima S, Haruta M, et al. (2008) Activation of antigen-specific cytotoxic T lymphocytes by beta2-microglobulin or TAP1 gene disruption and the introduction of recipient-matched MHC class I gene in allogeneic embryonic stem cell-derived dendritic cells. J Immunol 181: 6635–6643.
43. Bacak I, Cox JH, Anderson R, Yewdell JW, Bennink JR (1994) TAP transporter associated with antigen processing-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino- but not carboxyl-terminus of the peptide. J Immunol 152: 301–307.